{"denoms":[{"counts":[{"groupId":"BG000","value":"933"},{"groupId":"BG001","value":"468"},{"groupId":"BG002","value":"1401"}],"units":"Participants"}],"groups":[{"description":"Participants received 4 capsules of Enzalutamide 40 mg each (total dose 160 mg per day) orally, once daily in double-blind and open-label phase (up to a maximum of 68.8 months) until radiographic progression. Participants after last dose of study drug, were followed up for safety up to 30 days, and were long term followed up (for survival status and new prostate cancer therapies) from last dose to the death date or last known survival date.","id":"BG000","title":"Enzalutamide 160 mg"},{"description":"Participants received 4 capsules of placebo (matched to Enzalutamide) orally, once daily in double blind phase (up to a maximum of 51.3 months) until radiographic progression. Participants were given an opportunity to switch to open-label enzalutamide after completion of double blind phase. Participants after last dose of study drug, were followed up for safety up to 30 days and were long term followed up (for survival status and new prostate cancer therapies) to the death date or last known survival date.","id":"BG001","title":"Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.83","value":"73.8"},{"groupId":"BG001","spread":"7.63","value":"72.9"},{"groupId":"BG002","spread":"7.77","value":"73.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"933"},{"groupId":"BG001","value":"468"},{"groupId":"BG002","value":"1401"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"142"},{"groupId":"BG001","value":"88"},{"groupId":"BG002","value":"230"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"31"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"671"},{"groupId":"BG001","value":"320"},{"groupId":"BG002","value":"991"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"8"}]}],"title":"Multiple"},{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"20"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"116"}]}],"title":"Missing"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"The intent-to-treat (ITT) population was defined as all participants randomly assigned to study treatment and was based on randomized treatment assignment regardless of whether or not treatment was administered."}